IRTC vs. ZBH, SNN, SOLV, PEN, STVN, GKOS, NARI, TMDX, BLCO, and SLNO
Should you be buying iRhythm Technologies stock or one of its competitors? The main competitors of iRhythm Technologies include Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), TransMedics Group (TMDX), Bausch + Lomb (BLCO), and Soleno Therapeutics (SLNO). These companies are all part of the "medical equipment" industry.
iRhythm Technologies vs. Its Competitors
iRhythm Technologies (NASDAQ:IRTC) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.
In the previous week, Zimmer Biomet had 8 more articles in the media than iRhythm Technologies. MarketBeat recorded 14 mentions for Zimmer Biomet and 6 mentions for iRhythm Technologies. Zimmer Biomet's average media sentiment score of 1.21 beat iRhythm Technologies' score of 0.89 indicating that Zimmer Biomet is being referred to more favorably in the news media.
88.9% of Zimmer Biomet shares are owned by institutional investors. 0.7% of iRhythm Technologies shares are owned by company insiders. Comparatively, 0.7% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Zimmer Biomet has a net margin of 11.86% compared to iRhythm Technologies' net margin of -15.90%. Zimmer Biomet's return on equity of 12.73% beat iRhythm Technologies' return on equity.
iRhythm Technologies currently has a consensus target price of $138.60, suggesting a potential downside of 1.06%. Zimmer Biomet has a consensus target price of $111.33, suggesting a potential upside of 20.34%. Given Zimmer Biomet's higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than iRhythm Technologies.
iRhythm Technologies has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.
Zimmer Biomet has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.
Summary
Zimmer Biomet beats iRhythm Technologies on 12 of the 16 factors compared between the two stocks.
Get iRhythm Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
iRhythm Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:IRTC) was last updated on 7/7/2025 by MarketBeat.com Staff